Topotecan in small cell lung cancer

J. H. Schiller

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Lung cancer continues to be the leading cause of cancer-related death in both men and women. According to the American Cancer Society, 160,400 people are predicted to die from this disease in 1997. Approximately 20% to 25% of lung cancer cases are classified as small cell lung cancer (SCLC). Although initial response rates to chemotherapy and radiation therapy are high among SCLC patients, nearly all these patients will eventually relapse and require additional treatment. The search for better treatments in relapsed SCLC is thus a high priority. In particular, it is hoped that the availability of new non-cross-resistant chemotherapeutic agents such as topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a topoisomerase I inhibitor, will expand the treatment options. Because results from preclinical studies and phase I trials suggested that topotecan has activity in SCLC, the efficacy of this agent is currently being assessed in phase II and III clinical trials. Results from these trials, summarized here, suggest that topotecan may be a valuable alternative in the treatment of SCLC.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume24
Issue number6 SUPPL. 20
StatePublished - 1997

Fingerprint

Topotecan
Small Cell Lung Carcinoma
Lung Neoplasms
Topoisomerase I Inhibitors
Phase III Clinical Trials
Phase II Clinical Trials
Therapeutics
Radiotherapy
Recurrence
Drug Therapy
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Schiller, J. H. (1997). Topotecan in small cell lung cancer. Seminars in Oncology, 24(6 SUPPL. 20).

Topotecan in small cell lung cancer. / Schiller, J. H.

In: Seminars in Oncology, Vol. 24, No. 6 SUPPL. 20, 1997.

Research output: Contribution to journalArticle

Schiller, JH 1997, 'Topotecan in small cell lung cancer', Seminars in Oncology, vol. 24, no. 6 SUPPL. 20.
Schiller JH. Topotecan in small cell lung cancer. Seminars in Oncology. 1997;24(6 SUPPL. 20).
Schiller, J. H. / Topotecan in small cell lung cancer. In: Seminars in Oncology. 1997 ; Vol. 24, No. 6 SUPPL. 20.
@article{e7e90c3b1df3483da0a96b4cfc114267,
title = "Topotecan in small cell lung cancer",
abstract = "Lung cancer continues to be the leading cause of cancer-related death in both men and women. According to the American Cancer Society, 160,400 people are predicted to die from this disease in 1997. Approximately 20{\%} to 25{\%} of lung cancer cases are classified as small cell lung cancer (SCLC). Although initial response rates to chemotherapy and radiation therapy are high among SCLC patients, nearly all these patients will eventually relapse and require additional treatment. The search for better treatments in relapsed SCLC is thus a high priority. In particular, it is hoped that the availability of new non-cross-resistant chemotherapeutic agents such as topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a topoisomerase I inhibitor, will expand the treatment options. Because results from preclinical studies and phase I trials suggested that topotecan has activity in SCLC, the efficacy of this agent is currently being assessed in phase II and III clinical trials. Results from these trials, summarized here, suggest that topotecan may be a valuable alternative in the treatment of SCLC.",
author = "Schiller, {J. H.}",
year = "1997",
language = "English (US)",
volume = "24",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6 SUPPL. 20",

}

TY - JOUR

T1 - Topotecan in small cell lung cancer

AU - Schiller, J. H.

PY - 1997

Y1 - 1997

N2 - Lung cancer continues to be the leading cause of cancer-related death in both men and women. According to the American Cancer Society, 160,400 people are predicted to die from this disease in 1997. Approximately 20% to 25% of lung cancer cases are classified as small cell lung cancer (SCLC). Although initial response rates to chemotherapy and radiation therapy are high among SCLC patients, nearly all these patients will eventually relapse and require additional treatment. The search for better treatments in relapsed SCLC is thus a high priority. In particular, it is hoped that the availability of new non-cross-resistant chemotherapeutic agents such as topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a topoisomerase I inhibitor, will expand the treatment options. Because results from preclinical studies and phase I trials suggested that topotecan has activity in SCLC, the efficacy of this agent is currently being assessed in phase II and III clinical trials. Results from these trials, summarized here, suggest that topotecan may be a valuable alternative in the treatment of SCLC.

AB - Lung cancer continues to be the leading cause of cancer-related death in both men and women. According to the American Cancer Society, 160,400 people are predicted to die from this disease in 1997. Approximately 20% to 25% of lung cancer cases are classified as small cell lung cancer (SCLC). Although initial response rates to chemotherapy and radiation therapy are high among SCLC patients, nearly all these patients will eventually relapse and require additional treatment. The search for better treatments in relapsed SCLC is thus a high priority. In particular, it is hoped that the availability of new non-cross-resistant chemotherapeutic agents such as topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a topoisomerase I inhibitor, will expand the treatment options. Because results from preclinical studies and phase I trials suggested that topotecan has activity in SCLC, the efficacy of this agent is currently being assessed in phase II and III clinical trials. Results from these trials, summarized here, suggest that topotecan may be a valuable alternative in the treatment of SCLC.

UR - http://www.scopus.com/inward/record.url?scp=0031447057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031447057&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6 SUPPL. 20

ER -